Revolutionizing the Way We Treat Heart Failure
Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.
Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.
Company Details
- Employees
- 5
- Address
- 3 Chome-25-22 Tonomachi, Kawasaki,kanagawa 210-0821,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.metcela.com/en/
- Keywords
- cell therapy, heart failure, biotechnology.
- HQ
- Kawasaki, Kanagawa
Metcela Inc. Questions
Metcela Inc.'s website is https://www.metcela.com/en/
Metcela Inc.'s LinkedIn profile is https://jp.linkedin.com/company/metcela-inc
Metcela Inc. has
5 employees.
View email and phone details for 5
employees at Metcela Inc..
Metcela Inc.'s industry is
Biotechnology Research
Metcela Inc.'s top competitors are
Crescent Enterprises,
Beyond Next Ventures Inc.,
Bell Biosystems, Inc.,
Hishoh Biopharma Co., Ltd.,
Infcurion｜インフキュリオン,
Cathay Petroleum International Limited,
Lymphogenix,
Nomura,
Red Arrow Therapeutics,
Monovation株式会社.
Metcela Inc.'s categories are Biotechnology Research
